Eli Lilly CEO David Ricks on positive Alzheimer's drug trial data

Eli Lilly said on Monday a trial of its experimental Alzheimer’s drug donanemab showed it slowed by about a third the rate of decline in a combined measure of cognition and function in early-stage victims of the disease. Eli Lilly CEO David Ricks joined "Squawk Box" on Tuesday to discuss the positive data.